Paper Details

  1. Home
  2. Paper Details

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.

Author: CammererU, ColdeweyR, DeicherH, HeinR, HoffmannL, KonyarH, KreuserE D, PeestD, SelbachJ, von BroenI M

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 136 patients with multiple myeloma found that VBAMDex treatment led to a higher remission rate compared to melphalan and prednisone (MP) for stage III patients. MP was used to treat stage II patients with progressive disease. The study is ongoing, and survival data are not yet available.
Paper Details　
Original Abstract of the Article :
136 untreated multiple myeloma patients of stage II and III were collected in the study. 37/51 stage II patients had progressive disease and were treated with melphalan and prednisone (MP). 85 patients were of stage III and randomized into MP and vincristine, BCNU, adriamycin, melphalan and dexameth...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000216718

データ提供：米国国立医学図書館（NLM）

Melphalan and Prednisone vs. VBAMDex: A Head-to-Head Comparison in Multiple Myeloma

The battle against multiple myeloma requires innovative strategies and a deep understanding of treatment options. This research delves into the effectiveness of two distinct treatment regimens: melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex). The authors meticulously compared the responses of 136 untreated multiple myeloma patients to these regimens, revealing a higher response rate with VBAMDex. This is like comparing two different oases in the vast desert of multiple myeloma treatment, seeking the most effective path towards recovery.

VBAMDex: A Potential Advantage in Multiple Myeloma Treatment

This research suggests that VBAMDex may be a more effective treatment option for multiple myeloma compared to MP, as it achieved a significantly higher response rate in this study. However, it's important to note that the study is ongoing and further analysis is needed to determine long-term outcomes. While the results are promising, they require further investigation to confirm their significance. It's like finding a wellspring of hope in the desert of multiple myeloma, but it's essential to continue exploring its potential benefits.

A Journey Towards Better Treatment Options

This research emphasizes the importance of ongoing investigation and comparison of treatment options in the fight against multiple myeloma. It's a testament to the ongoing quest for better treatments and the commitment to improving patient outcomes. As we continue to explore the vast desert of multiple myeloma research, we're constantly seeking new and improved pathways to recovery.

Dr.Camel's Conclusion

This research, like a caravan venturing into the vast desert of multiple myeloma treatment, seeks to illuminate the most effective paths towards recovery. The authors' meticulous comparison of VBAMDex and MP regimens offers valuable insights into the battle against this challenging cancer, paving the way for future advancements in treatment strategies.

Date :
  1. Date Completed 1990-06-14
  2. Date Revised 2018-02-16
Further Info :

Pubmed ID

2186324

DOI: Digital Object Identifier

10.1159/000216718

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.